Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 104Stomach Neoplasms 19Inflammatory Breast Neoplasms 12Esophageal Neoplasms 11Triple Negative Breast Neoplasms 6Sarcoma 6Carcinoma, Hepatocellular 5Lymphoma, Large B-Cell, Diffuse 4Liver Neoplasms 4Adenocarcinoma Of Esophagus 4Primary Breast Cancer 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Hemangiosarcoma 3Unspecified Adult Solid Tumor, Protocol Specific 2Testicular Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasm Metastasis 2Malignant mesenchymal tumor 2Lymphoma, B-Cell, Marginal Zone 2Liposarcoma 2Hemangiopericytoma, Malignant 2Gallbladder Neoplasms 2Fibrosarcoma 2Desmoplastic Small Round Cell Tumor 2Chondrosarcoma 2Carcinoma, Ductal, Breast 2Breast Neoplasms, Male 2

Interventions

Paclitaxel 6Carboplatin 6Radiotherapy 5Chemotherapy, Adjuvant 5Cyclophosphamide 4Trastuzumab 3Tamoxifen 3Letrozole 3Doxorubicin 3Brachytherapy 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3pertuzumab 2Surgical Procedures, Operative 2Radiotherapy, Conformal 2Magnetic Resonance Spectroscopy 2Epirubicin 2talimogene laherparepvec 1sargramostim 1palbociclib 1ferric carboxymaltose 1atezolizumab 1atamestane 1aldesleukin 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1VPS Coriolus versicolor extract 1Toremifene 1Thiotepa 1Therapeutics 1Reverse Transcriptase Polymerase Chain Reaction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Ductal, Breast × Epirubicin × Clear all
NCT02682693 2021-02-02

GeparX

GBG Forschungs GmbH

Phase 2 Completed
780 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT02125344 2017-07-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

GBG Forschungs GmbH

Phase 3 Completed
961 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡